Literature DB >> 1577031

Arrhythmia profile in acromegaly.

G Kahaly1, K V Olshausen, S Mohr-Kahaly, R Erbel, S Boor, J Beyer, J Meyer.   

Abstract

In a controlled study, the cardiac involvement and arrhythmia profile of 32 patients with acromegaly were correlated with endocrine parameters (somatomedine C, growth hormone), clinical score and duration of the disease. Data were compared with those of 50 controls free of cardiac disease. Stress ECG, 24 h Holter monitoring and echocardiography were performed. Supraventricular premature complexes occurred no more often in acromegalics than in controls. Both prevalence and severity of ventricular arrhythmia, however, were significantly higher in patients compared to controls (P less than 0.01). 15/32 (48%) acromegalic patients had complex ventricular arrhythmias (Lown III-IV) as compared with 6/50 (12%) normal subjects (P less than 0.01). Repetitive ventricular arrhythmias (Lown IV a/b) occurred in 10/32 (31%) patients, but only in 4/50 (8%) controls (P less than 0.01). Furthermore, the frequency of ventricular premature complexes increased with duration of acromegaly (P less than 0.01). No correlation was found between the severity of ventricular arrhythmia and hormone levels. Left ventricular muscle mass was significantly increased (285 +/- 139 g, P less than 0.02) due to concentric hypertrophy. Severity of ventricular arrhythmias correlated with left ventricular mass and with clinical activity score (P less than 0.01). Thus, compared to controls, acromegalic patients show more frequent and complex ventricular arrhythmias and left ventricular hypertrophy. Duration of the disease rather than hormone levels seems to be relevant for these pathological changes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577031     DOI: 10.1093/oxfordjournals.eurheartj.a060047

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  26 in total

Review 1.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 2.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 3.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

4.  Atrial conduction times and left atrium mechanical functions in patients with active acromegaly.

Authors:  A Ilter; A Kırış; Ş Kaplan; M Kutlu; M Şahin; C Erem; N Civan; F Kangül
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

5.  Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues.

Authors:  A Comunello; F Dassie; C Martini; E De Carlo; R Mioni; M Battocchio; A Paoletta; F Fallo; R Vettor; P Maffei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

6.  QT dispersion in patients with acromegaly.

Authors:  Mustafa Unubol; Ufuk Eryilmaz; Engin Guney; Mevlut Ture; Cagdas Akgullu
Journal:  Endocrine       Date:  2012-11-13       Impact factor: 3.633

7.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 8.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.

Authors:  J Gilbert; M Ketchen; P Kane; T Mason; E Baister; M Monaghan; S Barr; P E Harris
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.

Authors:  G Lombardi; A Colao; P Marzullo; B Biondi; E Palmieri; S Fazio
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.